• Corpus ID: 14078807

Riboflavin and cancer: a review.

  title={Riboflavin and cancer: a review.},
  author={Richard S. Rivlin},
  journal={Cancer research},
  volume={33 9},
  • R. Rivlin
  • Published 1 September 1973
  • Biology, Medicine
  • Cancer research
Summary The relationship of riboflavin to cancer is intriguing but many gaps remain in our knowledge. Several studies indicate that riboflavin deficiency inhibits tumor growth in experimental animals and possibly in man, but the precise mechanisms involved have not been elucidated. Azo dye carcinogenesis in liver appears to be a special case in that riboflavin deficiency increases the potency of these drugs in tumor causation, probably in large measure because flavin cofactors are involved in… 

Tables from this paper

Riboflavin and health: A review of recent human research

An overview of the importance of riboflavin, its absorption and metabolism in health and diseased conditions, its deficiency and its association with various health diseases, and metabolic disorders is provided.

Riboflavin in Human Health: A Review of Current Evidences.

Effects of riboflavin deficiency upon concentrations of riboflavin, flavin mononucleotide, and flavin adenine dinucleotide in Novikoff hepatoma in rats.

The growth of Novikoff hepatoma did not alter hepatic riboflavin, flavin mononucleotide or FAD concentrations in either normal or rib oflavin-deficient rats, and the FAD pyrophosphorylase activity was increased in liver but not in tumor from ribofavin- deficient animals.

Putative role of riboflavin in disease prevention

Through deficiency and supplementation studies and effects on the structure and function of the small intestine, riboflavin has a role in iron handling and has also been ascribed arole in the protection against certain cancers and cataracts.

Riboflavin and Cancer

Tumors have been referred to as “nitrogen traps” that derive their amino acid supplies at the expense of the animal or human host and it appears that, when the supplies of dietary nitrogen are limited, tumor competes for them more successfully than normal host tissues.

Riboflavin as adjuvant with cisplatin: study in mouse skin cancer model.

Findings indicate that combination of cisplatin with riboflavin under photo illumination synergizes its anti cancer activity towards cancer cells and attenuates the cisPlatin induced toxicities.

Lumichrome Inhibits Human Lung Cancer Cell Growth and Induces Apoptosis via a p53-Dependent Mechanism

It is shown for the first time that unlike riboflavin, lumichrome can suppress lung cancer cell growth and reduce survival in both normal and anchorage-independent conditions.

Riboflavin: The Health Benefits of a Forgotten Natural Vitamin

It is appropriate to consider a re-evaluation of the importance of RF in terms of its beneficial properties following the latest findings about the link between RF and different clinical aberrations.

Disturbances in the formation of FAD and covalently bound flavins in Novikoff hepatoma from riboflavin-deficient rats.

The hypothesis that in conditions of rib oflavin deprivation, Novikoff hepatoma maintains the levels of the physiologically important flavin coenzymes at the expense of the free riboflavin fraction is supported.

Some interactions of light, riboflavin, and aflatoxin B1 in vivo and in vitro.

Low, carcinogenic doses of aflatoxin may complex with endogenous, photosensitized riboflavin, inhibiting its degradation into carcinogenic metabolites, and this interpretation gains support from studies in vitro that showed that rib oflavin quenched a flatoxin photodegradation, perhaps by complexing with aflat toxin.




With the objective of producing human riboflavin deficiency, an analog was sought that would be an effective rib oflavin antagonist in rodents and would be metabolized similarly in rodent and in man.

Riboflavin Protection Against Azo Dye Hepatoma Induction in the Rat 1

  • J. P. Lambooy
  • Biology
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine
  • 1970
In 1936 Kenosita demonstrated that feeding a diet containing 4-dimethylaminoazoben-zene (DAB) caused the production of hepatomas in the rat and this observation appears to have been the first evidence suggesting that nutrition might play a role in carcinogenesis.

Regulation of riboflavin-metabolizing enzymes in riboflavin deficiency.

The data demonstrate that riboflavin deficiency has selective effects upon the activities of liver enzymes involved in rib oflavin metabolism, and it is suggested that these effects may conshtute a possible adaptive mechanism for conserving FAD in ribofavin deficiency.

Experimental Dietary and Antagonist-Induced Human Riboflavin Deficiency

By the mid-1930s many clinical symptoms and signs attributable to riboflavin deficiency were described in pellagrins and in other dietary deficiencies. (7–9,31,46,58,62,73,82) The specificity of

Tetrahydrofolate-dependent enzyme activities of the rat liver in riboflavin deficiency.

Results of bioassay using L. casei, St. faecalis and Pediococcus cerevisiae of folate compounds of the liver revealed a tendency toward relative increase in folato deriva-tives other than N5 methyltetrahydrofolate in the liver of riboflavin deficient rats.

The Effect of Pyridoxine on Tumor Growth

A study was made of the response of a number of different types of tumors to synthetic diets low in pyridoxine, which included developing mouse tumors due to the injection or local application of methylcholanthrene, preformed primary mouse tumors, and three types of transplantable tumors.

The comparative pharmacology in man and the rat of the riboflavin analogu 6,7-dimethyl-9-(2-acetoxyethyl)-isoalloxazine, U-2112.

A species difference in metabolism of U-2112 may account for the ability of the drug to produce riboflavin deficiency in the rat and for its apparent inactivity in man.

Effects of iron, riboflavin and iodide deficiencies on hepatic drug-metabolizing enzyme systems.

The effects of three specific nutritional deficiencies (iron, riboflavin and iodide) on hepatic drug-oxidizing, -reducing and -glucuronidating systems, microsomal cytochromes and hexobarbital